Leerink Partnrs Predicts Increased Earnings for Equillium

Equillium, Inc. (NASDAQ:EQ) – Equities research analysts at Leerink Partnrs lifted their FY2024 EPS estimates for Equillium in a report released on Wednesday, November 13th. Leerink Partnrs analyst T. Smith now anticipates that the company will earn ($0.34) per share for the year, up from their prior estimate of ($0.61). The consensus estimate for Equillium’s current full-year earnings is ($0.12) per share. Leerink Partnrs also issued estimates for Equillium’s Q4 2024 earnings at ($0.27) EPS and FY2025 earnings at ($1.50) EPS.

Separately, HC Wainwright reiterated a “buy” rating and set a $5.00 target price on shares of Equillium in a research report on Monday, August 19th.

Equillium Price Performance

Shares of NASDAQ:EQ opened at $0.71 on Monday. Equillium has a 1 year low of $0.48 and a 1 year high of $3.25. The business’s 50-day moving average is $0.91 and its 200-day moving average is $0.96. The company has a market capitalization of $25.14 million, a price-to-earnings ratio of -5.07 and a beta of 1.83.

Insider Activity at Equillium

In related news, insider Penny Tom sold 38,806 shares of Equillium stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $0.85, for a total value of $32,985.10. Following the sale, the insider now owns 10,051 shares of the company’s stock, valued at approximately $8,543.35. The trade was a 79.43 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last three months, insiders sold 77,324 shares of company stock valued at $71,233. 30.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Equillium stock. Renaissance Technologies LLC boosted its holdings in shares of Equillium, Inc. (NASDAQ:EQ) by 43.6% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 300,400 shares of the company’s stock after buying an additional 91,200 shares during the period. Renaissance Technologies LLC owned approximately 0.85% of Equillium worth $208,000 as of its most recent SEC filing. Institutional investors own 27.05% of the company’s stock.

About Equillium

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.